# A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa

Source: https://onco.cc/trials/nct04680052/  
OnCo record `nct04680052` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tafasitamab, Rituximab, Lenalidomide in follicular lymphoma, run by Incyte Corporation, active and no longer recruiting.

## Summary

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. is a phase 3 interventional study registered as NCT04680052 by Incyte Corporation, with 654 participants enrolled, started 2021-04-15 and due to reach its primary completion in 2024-02-23. Interventions recorded: tafasitamab, rituximab, lenalidomide, placebo. Conditions listed: Follicular Lymphoma, Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04680052
- Phase: 3
- Setting: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
- Sponsor: Incyte Corporation
- Enrolled: 654

## Sources

- ClinicalTrials.gov NCT04680052: https://clinicaltrials.gov/study/NCT04680052

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct04680052.json